Zenotech Laboratories

Zenotech Laboratories Capital Intensity

The Capital Intensity Ratio of Zenotech Laboratories (532039.BO) as of Nov 22, 2026 is 280.96 %. In the previous year, Capital Intensity Ratio was 257.93 % — a change of 8.93% (higher).

Capital Intensity

280.96 %

YoY

8.93%

Last updated:

Capital Intensity Ratio of Zenotech Laboratories is 2026 280.96 % . Capital Intensity Ratio of Zenotech Laboratories was 2025 257.93 % . It decreases by 8.93% higher compared to the previous year.

The Zenotech Laboratories Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2019
649.19 INR
Jan 1, 2020
329.84 INR
Jan 1, 2021
443.11 INR
Jan 1, 2022
257.30 INR
Jan 1, 2023
237.77 INR
Jan 1, 2024
260.10 INR
Jan 1, 2025
257.93 INR
Jan 1, 2026
280.96 INR
The Zenotech Laboratories Capital Intensity history
YEARCapital IntensityYoY
280.96 %+8.93%
257.93 %-0.83%
260.10 %+9.39%
237.77 %-7.59%
257.30 %-41.93%
443.11 %+34.34%
329.84 %-49.19%
649.19 %-11.49%
733.49 %-67.42%
2,251.23 %-6.95%
2,419.39 %+54.72%
1,563.72 %-38.54%
2,544.44 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zenotech Laboratories Stock analysis

What does Zenotech Laboratories do? Zenotech Laboratories Ltd manufactures and markets pharmaceutical products, specializing in oncology, biotechnology, and general injectables. The company operates from a manufacturing facility in Turkapally village, Shamirpet Mandal, Telangana, producing specialty generic injectables for the pharmaceutical sector. Its products are sold to healthcare providers and distributors within the pharmaceutical industry, targeting markets that require specialized injectable solutions. The firm's business model focuses on the production and distribution of generic injectables, leveraging its facility in Telangana to serve both domestic and international markets. By concentrating on oncology and biotechnology injectables, Zenotech addresses specific medical needs, generating revenue through the sale of these high-demand pharmaceutical products to hospitals, clinics, and pharmaceutical distributors. Zenotech Laboratories Ltd's revenue streams come from the sale of its specialty generic injectables, including oncology and biotechnology products, to healthcare institutions and distribution networks. The company's manufacturing capabilities in Telangana support its role as a supplier in the pharmaceutical supply chain, with a focus on injectable formulations that cater to critical healthcare applications. Zenotech Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zenotech Laboratories stock

Capital Intensity Ratio of Zenotech Laboratories is 280.96 % in 2026.

Capital Intensity Ratio of Zenotech Laboratories changed from 257.93 % to 280.96 %, representing a 8.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio Zenotech Laboratories since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's Zenotech Laboratories with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Zenotech Laboratories

All Key Metrics — Zenotech Laboratories